未经证实：中国于2019年12月首次报道了急性肺炎病例（COVID-19），病原体被鉴定为SARS-CoV-2。目前,通过使用多个基因开发了许多针对这种病毒的疫苗，应用不同的平台，用于人群的疫苗接种。刺突蛋白基因在宿主细胞附着和病毒进入中起重要作用，已被广泛用于疫苗和抗病毒疗法的开发。短干扰RNA也被称为沉默RNA,并且有助于调节特定基因的表达。通过使用这项技术，病毒抑制已被证明对许多病毒性疾病。
UNASSIGNED：在这项工作中，我们已经报道了Insilico的预测，设计,和对SARS-CoV-2-S-RBD的siRNA抗病毒效力的实验验证。选择siDirect2.0用于siRNA预测，通过RNAfold预测二级结构，而HNADOCK用于分子对接分析和siRNA与所选靶标的特异性结合。我们已经使用并评估了四种siRNA的细胞毒性和基于q-real-timePCR在VeroE6细胞中的Ct值的抗病毒效率的测定。
UNASSIGNED：基于对生成数据的结果的实验评估和分析，我们观察到VeroE6细胞中任何测试的siRNA都没有细胞毒性。按照严格的选择和评分标准,从21个siRNA中过滤出总共4个siRNA。基于q-实时PCR的Ct值,在第三siRNA中观察到更好的抗病毒效率。从这项研究中得出的结果鼓励我们通过单独使用以及两种或更多种siRNA的组合来抑制SARS-CoV-2增殖来验证这些siRNA在多种细胞中的效率。
未经评估：Insilico预测，分子对接分析提供了更好的siRNA选择。基于实验评估,仅发现第三siRNA比其他siRNA更有效,并且显示出更好的抗病毒效率。这些siRNA也应在其他细胞系中单独或组合地针对SARS-CoV-2进行评估，以确定它们的抗病毒效率。
UNASSIGNED: The acute cases of pneumonia (COVID-19) were first reported from China in December 2019, and the pathogen was identified as SARS-CoV-2. Currently, many vaccines have been developed against this virus by using multiple genes, applying different platforms, and used for the vaccinations of the human population. Spike protein genes play an important role in host cell attachment and viral entry and have been extensively used for the development of vaccine and antiviral therapeutics. Short interfering RNA is also known as silencing RNA and contribute a significant role to regulate the expression of a specific gene. By using this technology, virus inhibition has been demonstrated against many viral diseases.
UNASSIGNED: In this work, we have reported the Insilico prediction, designing, and experimental validation of siRNAs antiviral potency against SARS-CoV-2-S-RBD. The siDirect 2.0 was selected for siRNAs prediction, and secondary structure was predicted by RNAfold while the HNADOCK was used for molecular docking analysis and specific binding of siRNAs to the selected target. We have used and evaluated four siRNAs for cellular toxicity and determination of antiviral efficiency based on the Ct value of q-real-time PCR in Vero E6 cells.
UNASSIGNED: Based on the experimental evaluation and analysis of results from generated data, we observed that there is no cytotoxicity for any tested siRNAs in Vero E6 cells. Total four siRNA were filtered out from twenty-one siRNAs following the strict selection and scoring criteria. The better antiviral efficiency was observed in 3rd siRNAs based on the Ct value of q-real-time PCR. The results that emerged from this study encouraged us to validate the efficiency of these siRNAs in multiple cells by using alone and in a combination of two or more siRNAs to inhibit the SARS-CoV-2 proliferation.
UNASSIGNED: The Insilico prediction, molecular docking analysis provided the selection of better siRNAs. Based on the experimental evaluation only 3rd siRNA was found to be more effective than others and showed better antiviral efficiency. These siRNAs should also be evaluated in other cell lines either separately or in combination against SARS-CoV-2 to determine their antiviral efficiency.
PDF(Pubmed)